Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

June 2014 - FRMC

06/19/2014

Tim Casey

Tim Casey
Tampa—Within the next 5 years, specialty pharmaceuticals are expected to account for more than half of the overall drug spending in the United States. By 2016, 8 of the top 10 branded drugs will be specialty medications, while 53 specialty...
Tampa—Within the next 5 years, specialty pharmaceuticals are expected to account for more than half of the overall drug spending in the United States. By 2016, 8 of the top 10 branded drugs will be specialty medications, while 53 specialty...
Tampa—Within the next 5 years,...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
The FDA approved oral medications—sofosbuvir and simeprevir—to treat hepatitis C.
The FDA approved oral medications—sofosbuvir and simeprevir—to treat hepatitis C.
The FDA approved oral...
06/19/2014
First Report Managed Care
06/19/2014

Kerri Fitzgerald

Kerri Fitzgerald
Tampa—Approximately 74% of patients with schizophrenia are nonadherent to oral antipsychotic medications. Even short treatment gaps with oral antipsychotics are associated with increased relapse risk, and 80% of patients with schizophrenia...
Tampa—Approximately 74% of patients with schizophrenia are nonadherent to oral antipsychotic medications. Even short treatment gaps with oral antipsychotics are associated with increased relapse risk, and 80% of patients with schizophrenia...
Tampa—Approximately 74% of...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
Orlando—In the United States, half of the 24 million people with chronic obstructive pulmonary disease (COPD) are undiagnosed. Still, a person dies from COPD every 4 minutes. The disease is the fourth leading cause of death and will be the...
Orlando—In the United States, half of the 24 million people with chronic obstructive pulmonary disease (COPD) are undiagnosed. Still, a person dies from COPD every 4 minutes. The disease is the fourth leading cause of death and will be the...
Orlando—In the United States,...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
According to the Centers for Disease Control and Prevention, 34.9% of adults in the United States are obese, while the estimated obesity-related costs are $147 billion per year.
According to the Centers for Disease Control and Prevention, 34.9% of adults in the United States are obese, while the estimated obesity-related costs are $147 billion per year.
According to the Centers for...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
Orlando—A 2011 report from the Institute of Medicine (IOM) found that chronic pain affects 116 million people in the United States, more than the total affected by heart disease, cancer, and diabetes combined. The disease also costs the...
Orlando—A 2011 report from the Institute of Medicine (IOM) found that chronic pain affects 116 million people in the United States, more than the total affected by heart disease, cancer, and diabetes combined. The disease also costs the...
Orlando—A 2011 report from the...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
San Diego—Patients with chronic obstructive pulmonary disease (COPD) who also had mild and moderate liver impairment or severe renal impairment tolerated a single orally-inhaled dose of olodaterol, according to 2 single-center, open-label...
San Diego—Patients with chronic obstructive pulmonary disease (COPD) who also had mild and moderate liver impairment or severe renal impairment tolerated a single orally-inhaled dose of olodaterol, according to 2 single-center, open-label...
San Diego—Patients with chronic...
06/19/2014
First Report Managed Care
06/19/2014

Tim Casey

Tim Casey
San Diego—Patients with idiopathic pulmonary fibrosis (IPF) who received 150 mg of nintedanib twice daily had a significant reduction in the rate of decline of forced vital capacity (FVC) compared with a placebo group, according to 2 phase 3,...
San Diego—Patients with idiopathic pulmonary fibrosis (IPF) who received 150 mg of nintedanib twice daily had a significant reduction in the rate of decline of forced vital capacity (FVC) compared with a placebo group, according to 2 phase 3,...
San Diego—Patients with...
06/19/2014
First Report Managed Care
06/19/2014

Mary Mihalovic

Mary Mihalovic
A recent study has shown that an 8-week regimen consisting of the antiviral agents ledipasvir and sofosbuvir was just as effective as a 12-week regimen in previously untreated patients with hepatitis C without cirrhosis [N Engl J Med. DOI:...
A recent study has shown that an 8-week regimen consisting of the antiviral agents ledipasvir and sofosbuvir was just as effective as a 12-week regimen in previously untreated patients with hepatitis C without cirrhosis [N Engl J Med. DOI:...
A recent study has shown that an...
06/19/2014
First Report Managed Care
06/19/2014

Mary Mihalovic

Mary Mihalovic
Combination treatment of ritonavir-enhanced ABT-450 with ombitasvir, dasabuvir, and ribavirin was shown to be effective in both previously treated and untreated patients with hepatitis C and compensated cirrhosis, according to a recent study...
Combination treatment of ritonavir-enhanced ABT-450 with ombitasvir, dasabuvir, and ribavirin was shown to be effective in both previously treated and untreated patients with hepatitis C and compensated cirrhosis, according to a recent study...
Combination treatment of...
06/19/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement